Content |
Biography
2023: Appointment as CEO of Nizhfarm
In mid-November 2023, the general director of the pharmaceutical company Nizhfarm changed: he was appointed Oksana Pozdnyakova, who previously headed the business division of over-the-counter drugs Consumer Healthcare of Stada in Russia. She headed the Nizhny Novgorod enterprise instead of Lyudmila Matveeva, who stayed at this post for a little over a year.
On November 15, 2023, Nizhfarm announced the appointment of a new general director Interfax with reference to the data of the Unified State Register of Legal Entities (Unified State Register of Legal Entities). It also follows from it that from November 1, the Luxembourg Nidda Lynx S.A.R.L. became the sole owner of Nizhfarm JSC Luxembourg (). She is in turn part of Nidda Healthcare Holding Gmb, the sole shareholder of Stada Arzneimittel AG. Prior to these changes, 100% of Nizhfarma was owned by Stada Arzneimittel.
On the Stada website, it is reported that Oksana Pozdnyakova began her career in the pharmaceutical industry at SmithKline Beecham/GlaxoSmithKline, and then held senior positions in Novartis Pharma and Sanofi.
Oksana Pozdnyakova joined Stada from Glenmark, where she served as vice president and CEO for Russia for two years.
Nizhpharm is a pharmaceutical enterprise for the production of finished medicines: ointments, gels, lines, suppositories, tablets and gelatin capsules.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |